Retatrutide and Birth Control

    By Trimi Medical Team11 min read

    The interaction between GLP-1 medications and oral birth control has become a significant concern since tirzepatide's label was updated with warnings about reduced contraceptive absorption. As a triple agonist with potent GLP-1 activity, retatrutide shares this concern. Additionally, weight loss itself can restore fertility in women with obesity-related anovulation, creating a "double fertility boost" that patients need to understand. Here is what the science says and what you should do (Jastreboff et al., NEJM 2023).

    Medical Disclaimer: This article is for informational purposes only. Retatrutide is an investigational drug not yet approved by the FDA. Discuss contraception strategies with your healthcare provider before starting any GLP-1 medication. Unplanned pregnancy during GLP-1 therapy carries unknown risks.

    How Retatrutide May Affect Oral Contraceptives

    Oral birth control pills rely on consistent absorption of hormones (ethinyl estradiol and progestins) through the gastrointestinal tract. Retatrutide significantly slows gastric emptying through its GLP-1 receptor activation, which can delay and potentially reduce the absorption of oral medications, including contraceptive hormones.

    The FDA required tirzepatide (Mounjaro/Zepbound) to include labeling about this interaction based on pharmacokinetic studies showing reduced oral contraceptive hormone levels. While specific studies with retatrutide have not been published, the same mechanism applies. The GLP-1-mediated delay in gastric emptying is a class effect shared by all GLP-1 receptor agonists, and retatrutide's potent GLP-1 activity suggests similar or greater impact.

    Which Birth Control Methods Are Affected

    MethodAffected by Retatrutide?Recommendation
    Oral contraceptive pillsYes - absorption may be reducedUse backup method or switch
    IUD (hormonal or copper)No - not affectedContinue as normal
    Implant (Nexplanon)No - not affectedContinue as normal
    Depo-Provera (injection)No - not affectedContinue as normal
    Patch (Xulane)No - transdermal absorptionContinue as normal
    Vaginal ring (NuvaRing)No - vaginal absorptionContinue as normal
    CondomsNo - barrier methodContinue as normal

    The Fertility Boost Effect

    Beyond the absorption concern, there is a second critical issue: weight loss itself can dramatically restore fertility. Obesity is a leading cause of anovulation (failure to ovulate regularly) and is strongly linked to polycystic ovary syndrome (PCOS). When women with obesity lose 10-15% of body weight, ovulation often resumes, sometimes before menstrual cycles even normalize visually.

    With retatrutide producing 20-24% weight loss, patients who were previously subfertile due to obesity may become significantly more fertile within months. This "Ozempic baby" phenomenon has been widely reported with semaglutide and tirzepatide. Retatrutide's more dramatic weight loss may make this fertility restoration even more pronounced.

    Recommended Contraception Strategy

    For women of childbearing potential starting retatrutide, the following approach is recommended:

    • Best options: Non-oral methods (IUD, implant, Depo-Provera, patch, or ring) that bypass the GI tract entirely
    • If continuing oral pills: Use a backup barrier method (condoms) during the first 4-8 weeks and after each dose escalation
    • Consider switching: Talk to your OB/GYN about transitioning from oral contraceptives to a long-acting reversible contraception (LARC) method before starting retatrutide
    • Timing for oral pills: If continuing oral contraceptives, take them at least 1 hour before or after any food, and consider taking them at a time when gastric emptying is least affected (such as first thing in the morning on an empty stomach)

    If You Want to Get Pregnant

    Retatrutide should be stopped well before conception. Based on class guidance for GLP-1 medications, providers typically recommend discontinuing retatrutide at least 2 months before trying to conceive. This washout period allows the drug to clear the body and gastric motility to normalize. There are no fertility benefits to being on retatrutide during conception, and the effects of GLP-1 medications on fetal development are not well studied.

    GI Side Effects and Birth Control

    Vomiting is an additional concern for oral contraceptive users. If vomiting occurs within 2 hours of taking a birth control pill, the hormones may not have been absorbed. GLP-1 medications can cause vomiting, particularly during dose escalation. Patients on oral contraceptives should use a backup method if vomiting occurs and follow their specific pill's missed-dose instructions.

    GLP-1 Treatment With Comprehensive Care

    Trimi offers compounded semaglutide ($99/month) and compounded tirzepatide ($125/month) with medical teams who address all medication interactions, including contraception. Learn how Trimi works.

    Frequently Asked Questions

    Will retatrutide make my birth control pill less effective?

    Potentially yes. Delayed gastric emptying can reduce oral contraceptive absorption. Consider using a non-oral method or adding a backup barrier method during retatrutide treatment.

    Is the IUD the best option while on retatrutide?

    IUDs (both hormonal and copper) are excellent choices because they are not affected by gastric emptying changes. Implants and injections are also unaffected. Any non-oral method eliminates the absorption concern.

    Can retatrutide increase fertility?

    Indirectly, yes. Weight loss from retatrutide can restore ovulation in women with obesity-related anovulation or PCOS. This fertility restoration can happen quickly, sometimes within the first few months of treatment.

    How long should I stop retatrutide before trying to conceive?

    Most providers recommend stopping GLP-1 medications at least 2 months before planned conception. Discuss your specific timeline with your healthcare provider.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date., Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg., Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial, the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: December 13, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    - Sarah MillerFacebook
    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    - Veronica LarimoreFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1), NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Complete guide covering GLP-1 medications with the fewest GI side effects in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredient

    Complete guide covering affordable telehealth weight loss programs in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ingredients at up

    Complete guide covering the best online weight loss medication providers in 2026 in 2026. Compare options, understand pricing, and discover how compounded GLP-1 medications deliver the same active ing

    Track retatrutide pricing as it develops. Estimated brand-name costs, insurance coverage prospects, compounding pharmacy options, and how to access affordable GLP-1 treatment now.

    Start your GLP-1 journey, from $99/mo

    Get Started